China’s electrophysiology ablation market CAGR to reach 15% through 2033

Key growth drivers include the advancements in pulsed field technology and the adoption of new products. 

China’s electrophysiology ablation market is forecasted to witness a compound annual growth rate (CAGR) of 15% through 2033, according to a GlobalData report.

The market is driven by the rising prevalence of atrial fibrillation and the growing demand for minimally invasive procedures.

Moreover, its expansion is attributed to the advancements in pulsed field technology and the adoption of new products such as the recent approval of Boston Scientific’s Farapulse for atrial fibrillation treatment.

“This marks a significant milestone, as the country’s electrophysiology devices market had limited options earlier with only one pulsed field ablation (PFA) product available,” the report said.

Building on this, GlobalData Medical Devices Analyst, Jyoti Sharma, mentioned that most clinicians are expected to favor PFA catheters over alternative technologies due to fewer associated complications.

This translates to reduced procedure times for faster patient recovery and shortened hospital stays.

“The rapid adoption of PFA will revolutionise atrial fibrillation treatment, providing patients with safer, more effective options and setting a new standard in cardiovascular care globally,” Sharma said.